Pegylated Interferon vs Standard Interferon for Chronic Hepatitis C—Reply Fabrice Carrat, MD, PhD; Firouzé Bani-Sadr, MD; Patrice Cacoub, MD; et al Stanislas Pol, MD, PhD; Christian Perronne, MD, PhD; for the ANRS HC02-RIBAVIC Study Team Author Affiliations JAMA. 2005;293(11):13...
Results: More patients had sustained virologic responses in the peginterferon group than in the standard interferon group (27%vs 20%,P=.047). This difference between the treatments was found in patients with HCV genotype 1 or 4 infection (17%for peginterferon vs 6%for standard interferon,P=....
Pegylated interferon α2b versus pegylated interferon α2a for chronic hepatitis C: The unreached goal of superioritydoi:10.1016/j.jhep.2009.09.013Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW,...
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlle
A randomized trial of pegylated interferon alpha-2B and ribavirin vs. pegylated interferon alone in patients with chronic hepatitis C who have failed standard therapy. Interim results after 24 weeks: Jeffrey D Bornstein MD, FRCPC, Andrew J Muir MD, Paul G Killenberg MD, Duke Univ Medical Ctr,...
Human immunodeficiency virus IFN-α: Interferon-α LAM: Lamivudine LdT: Telbivudine NUCs: Nucleos(t)ide analogues PEG-IFN-α-2a: Pegylated interferon α-2a TDF: Tenofovir References Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt EH, Hull AR, Carter NW. Glomerulonephritis wit...
542JHuazhongUnivSciTcchnol[MedSci]34(4):542.547,2014DOIl0.1007/sl1596.014.13l2—2CombinationTherapywithPegylatedInterferonalpha·-2bandAdefovirDipivoxilinHBeAg-·positiveChronicHepatitisBversusInterferonAlone:AProspective,RandomizedStudyYu.huaLIU(刘育华)十,TaoWU(吴涛)十,NingSUN(孙宁),Guang.1iWANG(王光丽),...
A multicenter, randomized trial of combination pegylated interferon-alpha 2a plus ribavirin vs. pegylated interferon-alpha 2A monotherapy in liver transplant recipients with Recurrent hepatitis CE.J., GaneS.I., StrasserD.H., CrawfordJ.A., Ring...
A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 μg dose of the pegyl
Objective To evaluate the effect of pegylated interferon in combination with Ribavirin in previous nonresponders or relapsers of chronic hepatitis C,and to analyze the factors that may affect the efficacy of treatment.Methods This is an open,prospective cohort study.The nonresponders and relapsers we...